Adipose-Derived Stromal Cells for Treatment of Patients with Chronic Ischemic Heart Disease (MyStromalCell Trial): A Randomized Placebo-Controlled Study

Autor: Abbas Ali Qayyum, Anders Bruun Mathiasen, Naja Dam Mygind, Jørgen Tobias Kühl, Erik Jørgensen, Steffen Helqvist, Jens Jørgen Elberg, Klaus Fuglsang Kofoed, Niels Groove Vejlstrup, Anne Fischer-Nielsen, Mandana Haack-Sørensen, Annette Ekblond, Jens Kastrup
Jazyk: angličtina
Rok vydání: 2017
Předmět:
Zdroj: Stem Cells International, Vol 2017 (2017)
Druh dokumentu: article
ISSN: 1687-966X
1687-9678
DOI: 10.1155/2017/5237063
Popis: We aimed to evaluate the effect of intramyocardial injections of autologous VEGF-A165-stimulated adipose-derived stromal cells (ASCs) in patients with refractory angina. MyStromalCell trial is a randomized double-blind placebo-controlled study including sixty patients with CCS/NYHA class II-III, left ventricular ejection fraction > 40%, and at least one significant coronary artery stenosis. Patients were treated with ASC or placebo in a 2 : 1 ratio. ASCs from the abdomen were culture expanded and stimulated with VEGF-A165. At 6 months follow-up, bicycle exercise tolerance increased significantly in time duration 22 s (95%CI −164 to 208 s) (P=0.034), in watt 4 (95%CI −33 to 41, 0.048), and in METs 0.2 (95%CI −1.4 to 1.8) (P=0.048) in the ASC group while there was a nonsignificant increase in the placebo group in time duration 9 s (95%CI −203 to 221 s) (P=0.053), in watt 7 (95%CI −40 to 54) (P=0.41), and in METs 0.1 (95%CI −1.7 to 1.9) (P=0.757). The difference between the groups was not significant (P=0.680, P=0.608, and P=0.720 for time duration, watt, and METs, resp.). Intramyocardial delivered VEGF-A165-stimulated ASC treatment was safe but did not improve exercise capacity compared to placebo. However, exercise capacity increased in the ASC but not in the placebo group. This trial is registered with ClinicalTrials.gov NCT01449032.
Databáze: Directory of Open Access Journals
Externí odkaz: